Cushing’s syndrome is a disorder
that occurs when your body makes too much of the hormone cortisol over a long
period of time.
The report provides a
comprehensive view of disease events, types, severity level, identified and
emerging biomarkers, progression, manifestations, symptoms, risk factors,
pathogenesis, genetic basis and treatment guidelines at country level.
Etiology:
Cushing’s syndrome can be caused
by overuse of cortisol medication, as seen in the treatment of chronic asthma
or rheumatoid arthritis (iatrogenic Cushing’s syndrome), excess production of
cortisol from a tumor in the adrenal gland or elsewhere in the body (ectopic Cushing’s
syndrome) or a tumor of the pituitary gland secreting adrenocorticotropic
hormone (ACTH) which stimulates the over-production of cortisol from the
adrenal gland (Cushing’s disease).
Epidemiology:
An estimated 10-15 per million people are affected every
year.
Geography Covered
* North America- United States and Canada
* EU5- Germany, France, Italy, Spain, and the United Kingdom
* Other EU Countries- Sweden, Denmark, Austria, Finland,
Belgium, Netherlands, Switzerland, Poland, Russia
* Japan
* APAC- Singapore, China, India, New Zealand, Australia
* LATAM- Brazil, Mexico, Argentina
* Middle East (Israel, Saudi Arabia and the United Arab
Emirates, Morocco, Egypt, Turkey, Algeria).
Current Clinical
Practice and Treatment Algorithm
Country-specific current clinical
practice, the standard of care, and significant limitations around addressing
the unmet needs are being covered under this section of the study.
Retrospective analysis and bench-marking of clinical study outcomes are being
presented in terms of Pr-treatment & post-treatment clinical and
demographic patient characteristics.
KOL
Insights - KOLs across 8 MM
market from center of Excellence/ Public/ Private hospitals participated in the
study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
Competitive
Landscape:
Competitive landscape includes
country specific approved as well as pipeline therapies. Any asset/ product
specific designation or review such as Orphan drug designation, Fast track,
Priority review, Breakthrough Therapy Designation, Rare Pediatric Disease
Designation and Accelerated Approval are being tracked and supplemented with
analyst commentary.
Clinical Trial
Assessment:
Detailed clinical trial data
analysis and key product positioning includes trial design, primary outcomes,
secondary outcomes, dosing and schedules, inclusion and exclusion criteria,
recruitment status and essentially covers the reported adverse events.
Market
Forecasting - Thelansis’ research team expects the Cushing’s syndrome
market potential for 2030 at $X.XXB in 8MM countries. Out of this market, 68.5%
sales are expected to be contributed from the US market whereas XX.X% is
expected to come from EU-5. Japan and China are expected to contribute XX.X%
and X.X% respectively.
Patient Based Forecast Model (MS. Excel Based Automated
Dashboard)
- Data Inputs with sourcing
- Market Event and Product Event
- Country specific Forecast Model
- Market uptake and patient share uptake
Unmet Medical Needs
Overview:
This report presents the most
important clinical unmet needs in the treatment, according to Thelansis’s primary
market research and analysis. Other important unmet needs identified
through our research, include decreased cost burden on patients, improved
administration convenience, and improved patient compliance. Our Syndicated
research reports include Market Insight, Pipeline Insight, Product Insight,
Specialized Reports, Indication Outlook and Market Access Reports.
Thelansis is specialized in Therapy Area Landscape Analysis along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products.
No comments:
Post a Comment